Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157485 | 0.96 | TSHR (0.46) | TSHRLMNATHRBALDH1A1TDP1 | |
| Lithium Ion SCHEMBL9420075 | 0.92 | TSHR (0.43) | TSHRLMNATHRBALDH1A1TDP1 | |
| SCHEMBL31130730 | 0.92 | TSHR (0.43) | TSHRLMNATHRBALDH1A1TDP1 | |
| SCHEMBL15799696 | 0.89 | TSHR (0.47) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Ammonia Solution, Strong SCHEMBL4761998 | 0.89 | TSHR (0.47) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Tetramethylammonium Ion SCHEMBL8572898 | 0.86 | TSHR (0.38) | TSHRLMNATHRBSLC22A1SLC22A2 | |
| SCHEMBL2875141 | 0.85 | TSHR (0.50) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Boric Acid SCHEMBL15798176 | 0.83 | ANPEP (0.43) | TSHRLMNATHRBALDH1A1SMN1; SMN2 | |
| SCHEMBL8757259 | 0.81 | TSHR (0.40) | TSHRLMNATHRBALDH1A1TDP1 | |
| Potassium Ion SCHEMBL5672140 | 0.81 | TSHR (0.47) | TSHRLMNATHRBALDH1A1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594625-A | Method for preparing bazedoxifene | 济南明微医药科技有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-109072484-B | Graphene fiber and preparation method thereof | 汉阳大学校产学协力团 | 2021-06-04 | — | — | CN | disclosed |
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO.,LTD. | 2008-03-13 | — | — | US | disclosed |
| US-7300917-B2 | Remedy for chronic disease | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20060135577-A1 | Remedy for chronic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | EDNRA, EDNRB, LPAR2 | TSHR 1195/4885LMNA 2447/4885THRB 1080/4885 |
| US-20060135577-A1 | Remedy for chronic disease | EDNRA, EDNRB, LPAR2 | TSHR 1195/4885LMNA 2447/4885THRB 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.